Ensysce Biosciences (ENSC) Competitors $2.24 +0.04 (+1.82%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.24 +0.00 (+0.22%) As of 07/25/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENSC vs. FNCH, SONN, MRKR, RVPH, RLMD, BLRX, LEXX, IXHL, RLYB, and ASBPShould you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Finch Therapeutics Group (FNCH), Sonnet BioTherapeutics (SONN), MARKER THERAPEUTICS (MRKR), Reviva Pharmaceuticals (RVPH), Relmada Therapeutics (RLMD), BioLineRx (BLRX), Lexaria Bioscience (LEXX), Incannex Healthcare (IXHL), Rallybio (RLYB), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry. Ensysce Biosciences vs. Its Competitors Finch Therapeutics Group Sonnet BioTherapeutics MARKER THERAPEUTICS Reviva Pharmaceuticals Relmada Therapeutics BioLineRx Lexaria Bioscience Incannex Healthcare Rallybio Aspire Biopharma Finch Therapeutics Group (NASDAQ:FNCH) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has better earnings and valuation, FNCH or ENSC? Ensysce Biosciences has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.42Ensysce Biosciences$5.21M1.02-$7.99M-$6.54-0.34 Does the media refer more to FNCH or ENSC? In the previous week, Ensysce Biosciences had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Ensysce Biosciences and 0 mentions for Finch Therapeutics Group. Ensysce Biosciences' average media sentiment score of 1.89 beat Finch Therapeutics Group's score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Finch Therapeutics Group Neutral Ensysce Biosciences Very Positive Which has more volatility and risk, FNCH or ENSC? Finch Therapeutics Group has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Is FNCH or ENSC more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -109.49%. Finch Therapeutics Group's return on equity of -69.14% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Ensysce Biosciences -109.49%-192.54%-121.77% Do insiders and institutionals have more ownership in FNCH or ENSC? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryFinch Therapeutics Group and Ensysce Biosciences tied by winning 6 of the 12 factors compared between the two stocks. Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENSC vs. The Competition Export to ExcelMetricEnsysce BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.22M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.69%4.01%P/E Ratio-0.3421.1828.1020.06Price / Sales1.02283.55428.7189.10Price / CashN/A42.7636.2258.56Price / Book0.868.378.665.87Net Income-$7.99M-$55.19M$3.25B$258.55M7 Day Performance5.16%5.88%4.22%3.73%1 Month Performance0.90%17.33%10.51%11.75%1 Year Performance-65.10%4.42%34.40%18.02% Ensysce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENSCEnsysce Biosciences0.9409 of 5 stars$2.24+1.8%N/A-63.8%$5.22M$5.21M-0.3410Positive NewsFNCHFinch Therapeutics GroupN/A$12.29-1.7%N/A+578.4%$19.74MN/A-1.39190SONNSonnet BioTherapeutics3.9663 of 5 stars$5.15-16.7%$20.00+288.3%-41.3%$19.57M$20K0.0010Positive NewsGap DownMRKRMARKER THERAPEUTICS4.5448 of 5 stars$1.53-10.0%$13.17+760.6%-70.2%$19.24M$6.59M-1.1560Gap UpHigh Trading VolumeRVPHReviva Pharmaceuticals3.3798 of 5 stars$0.40-1.0%$9.00+2,176.8%-62.6%$19.16MN/A-0.505Positive NewsGap UpHigh Trading VolumeRLMDRelmada Therapeutics4.8117 of 5 stars$0.61+6.4%$5.00+714.3%-84.0%$19.15MN/A-0.2410Positive NewsGap DownBLRXBioLineRx2.7973 of 5 stars$4.36-2.5%$26.00+496.3%-87.8%$19.05M$28.94M-0.5040Positive NewsLEXXLexaria Bioscience2.2435 of 5 stars$0.95+1.0%$5.00+423.7%-68.3%$18.49M$460K-1.427IXHLIncannex Healthcare0.73 of 5 stars$0.82+34.4%N/A-51.4%$17.95M$10K-0.683News CoverageGap DownHigh Trading VolumeRLYBRallybio2.8586 of 5 stars$0.46+7.5%$10.00+2,063.1%-62.5%$17.89M$640K-0.4240Positive NewsASBPAspire BiopharmaN/A$0.41+14.1%N/AN/A$17.73MN/A0.00N/ANews CoverageGap Down Related Companies and Tools Related Companies FNCH Alternatives SONN Alternatives MRKR Alternatives RVPH Alternatives RLMD Alternatives BLRX Alternatives LEXX Alternatives IXHL Alternatives RLYB Alternatives ASBP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENSC) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
